aTyr Pharma Inc
NASDAQ:ATYR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
aTyr Pharma Inc
NASDAQ:ATYR
|
86.2m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
89B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
aTyr Pharma Inc
Glance View
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for aTyr Pharma Inc is -39 537.9%, which is below its 3-year median of -14 277.8%.
Over the last 3 years, aTyr Pharma Inc’s Net Margin has decreased from -436.5% to -39 537.9%. During this period, it reached a low of -39 537.9% on Oct 30, 2025 and a high of -401.8% on Sep 30, 2023.
